Patient

IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

Saturday, September 18, 2021 - 4:30pm

Susan Galbraith, Executive Vice President, Oncology R&D, said: This remarkable improvement in survival is an unprecedented achievement at three years for patients with extensive-stage small cell lung cancer.

Key Points: 
  • Susan Galbraith, Executive Vice President, Oncology R&D, said: This remarkable improvement in survival is an unprecedented achievement at three years for patients with extensive-stage small cell lung cancer.
  • IMFINZI plus chemotherapy continued to demonstrate a well-tolerated safety profile consistent with the known profiles of these medicines.
  • Results showed 32.5% of patients experienced a serious adverse event (all causality) with IMFINZI plus chemotherapy versus 36.5% with chemotherapy alone.
  • In June 2019, AstraZeneca announced the CASPIAN Phase III trial had met one primary endpoint of demonstrating OS for IMFINZI plus chemotherapy at a planned interim analysis.

IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer

Saturday, September 18, 2021 - 4:30pm

Susan Galbraith, Executive Vice President, Oncology R&D, said: This remarkable improvement in survival is an unprecedented achievement at three years for patients with extensive-stage small cell lung cancer.

Key Points: 
  • Susan Galbraith, Executive Vice President, Oncology R&D, said: This remarkable improvement in survival is an unprecedented achievement at three years for patients with extensive-stage small cell lung cancer.
  • IMFINZI plus chemotherapy continued to demonstrate a well-tolerated safety profile consistent with the known profiles of these medicines.
  • Results showed 32.5% of patients experienced a serious adverse event (all causality) with IMFINZI plus chemotherapy versus 36.5% with chemotherapy alone.
  • In June 2019, AstraZeneca announced the CASPIAN Phase III trial had met one primary endpoint of demonstrating OS for IMFINZI plus chemotherapy at a planned interim analysis.

DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit

Saturday, September 18, 2021 - 2:33pm

For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.

Key Points: 
  • For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.
  • Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.
  • For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .

ARDX INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc.

Saturday, September 18, 2021 - 3:02pm

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law.

Key Points: 
  • Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.
  • For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .
  • Kessler Topaz Meltzer & Check, LLP

 Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)

Saturday, September 18, 2021 - 2:34pm

This marks the first time a monoclonal antibody treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS.

Key Points: 
  • This marks the first time a monoclonal antibody treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS.
  • The administration time for the recommended dosage of regdanvimab (CT-P59), a single intravenous (IV) infusion of 40 mg/kg, has been reduced from 90 minutes to 60 minutes.
  • Regdanvimab is the first of its kind for the treatment of COVID-19, so the efficacy and safety profile should be assessed thoroughly.
  • As of September 2021, more than 14,857 people have been treated with regdanvimab (CT-P59) in 107 hospitals in the Republic of Korea.

Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021

Saturday, September 18, 2021 - 1:45pm

This data is from 48 first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations who received 16mg of oral poziotinib once daily.

Key Points: 
  • This data is from 48 first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations who received 16mg of oral poziotinib once daily.
  • There currently is no specific approved treatment for NSCLC patients with HER2 exon 20 insertion mutations.
  • Cohort 4 of the ZENITH20 clinical trial is enrolling treatment-nave NSCLC patients with HER2 exon 20 insertion mutations.
  • Poziotinib demonstrated clinically meaningful anti-tumor activity in newly diagnosed NSCLC patients with HER2 exon 20 mutations with 16mg QD dosing.

Epic Sciences Comprehensive Cancer Profiling Platform Shows Compelling Value Of Cell Analysis In Data Presented At ESMO Congress 2021

Saturday, September 18, 2021 - 12:59pm

SAN DIEGO, Sept. 18, 2021 /PRNewswire/ -- Epic Sciences , Inc.'s (Epic) Comprehensive Cancer ProfilingPlatform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate.

Key Points: 
  • SAN DIEGO, Sept. 18, 2021 /PRNewswire/ -- Epic Sciences , Inc.'s (Epic) Comprehensive Cancer ProfilingPlatform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate.
  • "Biomarker analysis is ongoing in this and other studies comparing the Epic Sciences PSMA CTC Assay with PSMA and FDG PET imaging, and patient outcomes.
  • The company's Comprehensive Cancer Profiling Platform, leverages proven and proprietary CTC capabilities, and adds ctDNA and immune cell analysis, to provide more complete data for more efficient analysis and clearer insights.
  • Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes.

Preventing COVID-19 with Photodisinfection – New Results Presented at European Society of Photobiology

Saturday, September 18, 2021 - 6:27am

[3]

Key Points: 
  • [3]
    Ondine Biomedical, which specializes in photodisinfection-based medical devices, presented in vitro and in vivo results which demonstrated elimination of the SARS-CoV-2 genome after less than a few minutes of photodisinfection treatment at the recent European Society of Photobiology conference in Austria.
  • Ondines photodisinfection technology was also shown to destroy spike protein and receptor binding domains from various major viral variants including the highly infectious Delta variant from India.
  • Dr. Nicolas Loebel, President and Chief Technology Officer, told the meeting, The nose is a major reservoir of SARS-CoV-2.
  • Ondine has developed a patented, painless, photodisinfection technology platform used in treatment and prevention therapies for a broad-spectrum of pathogens - bacterial, viral and fungal - including multidrug-resistant strains.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX

Saturday, September 18, 2021 - 12:15am

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.

Key Points: 
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Ronald O. Royce, D.O. is recognized by Continental Who's Who

Friday, September 17, 2021 - 10:34pm

is recognized by Continental Who's Who as a Trusted Orthopedic Surgeon for his outstanding contributions in the field of Orthopedics and his professional excellence at Centura Orthopedics.

Key Points: 
  • is recognized by Continental Who's Who as a Trusted Orthopedic Surgeon for his outstanding contributions in the field of Orthopedics and his professional excellence at Centura Orthopedics.
  • As the region's largest healthcare network, Centura Orthopedics is dedicated to fulfilling the healthcare needs of those they serve.
  • Having garnered over thirty years of orthopedic experience, Dr. Ronald O. Royce specializes in shoulder and knee orthopedic surgeries.
  • Thereafter, Dr. Royce would then go on to complete his Total Joint Replacement Surgical residency at Brigham and Women's Hospital.